

WHAT IS CLAIMED IS:

1. A method of treating rhinosinusitis in a subject, the method comprising:
identifying a subject having rhinosinusitis; and
administering to the subject an effective amount of verapamil and mometasone.
2. A method of enhancing corticosteroid retention in a subject's sinonasal epithelial cells, the method comprising:
identifying a subject overexpressing P-gp in the subject's sinonasal epithelial cells; and
administering to the subject an effective amount of verapamil and mometasone.
3. A method of reducing inflammation in a subject's sinonasal epithelial cells, the method comprising:
identifying a subject overexpressing P-gp in the subject's sinonasal epithelial cells; and
administering to the subject an effective amount of verapamil and mometasone.
4. The method of claim 2 or claim 3, wherein identifying a subject overexpressing P-gp in the subject's sinonasal epithelial cells comprises providing a sample comprising nasal secretions, preferably comprising nasal mucus, from a subject; determining a level of soluble p-glycoprotein (P-gp) in the sample; and comparing the level of P-gp in the sample to a reference level of P-gp; wherein a level of P-gp in the sample above the reference level indicates that the subject overexpresses P-gp.
5. The method of any of the preceding claims, wherein the subject has chronic rhinosinusitis (CRS) or CRS with nasal polyps (CRSwNP).

6. The method of any of the preceding claims, wherein the verapamil and mometasone are administered systemically.

7. The method of any of the preceding claims, wherein the verapamil and mometasone are administered locally to the subject's nasal passage and sinuses.

8. The method of claim 7, wherein the verapamil and mometasone are delivered to the subject's nasal passage and sinuses by nasal irrigation.

9. The method of claim 8, wherein the nasal irrigation is high volume, low positive pressure nasal irrigation.

10. The method of claim 9, wherein the verapamil and mometasone are delivered to the subject's nasal passage and sinuses by high volume, low positive pressure nasal irrigation with a saline solution.

11. The method of claim 10, wherein the saline solution is an isotonic saline solution.

12. The method of claim 10, wherein the saline solution is a hypertonic saline solution.

13. The method of claim 12, wherein the hypertonic saline solution is about a 2% w/v saline solution.

14. The method of any one of claims 1–5, wherein the verapamil and mometasone are administered to the subject as a verapamil and mometasone eluting implant placed in the subject's nasal passage or sinuses.

15. The method of claim 14, wherein the implant is bioabsorbable.

16. The method of any one of claims 1–5, wherein the verapamil is administered to the subject's nasal passage and sinuses by nasal irrigation and the

mometasone is administered to the subject as a mometasone eluting implant placed in the subject's nasal passage or sinuses.

17. The method of any of the preceding claims, wherein the subject having rhinosinusitis was identified by endoscopy.

18. The method of any of the preceding claims, wherein the subject having rhinosinusitis was identified by computed tomography.

19. The method of any of the preceding claims, wherein the subject having rhinosinusitis was identified by observing the subject's symptoms and duration of symptoms.

20. The method of any of the preceding claims, further comprising monitoring the efficacy of the treatment by endoscopy.

21. The method of any of the preceding claims, further comprising monitoring the efficacy of the treatment by computed tomography.

22. The method of any of the preceding claims, further comprising monitoring the efficacy of the treatment by observing the subject's symptoms and duration of symptoms.

23. The method of any of the preceding claims, further comprising surgically removing any nasal polyps present in the subject.

24. The method of any of the preceding claims, wherein the verapamil and mometasone are administered in combination with an antibiotic.

25. The method of any of the preceding claims, wherein the antibiotic is selected from erythromycin or a pharmaceutically acceptable salt thereof, doxycycline or a pharmaceutically acceptable salt thereof, tetracycline or a pharmaceutically acceptable salt thereof, penicillin or a pharmaceutically acceptable salt thereof, beta-lactam or a pharmaceutically acceptable salt thereof, macrolide or a pharmaceutically

acceptable salt thereof, fluoroquinolone or a pharmaceutically acceptable salt thereof, cephalosporin or a pharmaceutically acceptable salt thereof, and sulfonamide or a pharmaceutically acceptable salt thereof.

26. A kit for treating rhinosinusitis in a subject, said kit comprising
a pharmaceutical composition comprising an effective amount of
verapamil and mometasone; and
a device for delivering the pharmaceutical composition to the subject's
nasal passage and sinuses.

27. The kit of claim 26, wherein said device delivers the pharmaceutical
composition to the subject's nasal passage and sinuses in a liquid, nebulized, or
aerosolized form.

28. The kit of claim 26 or claim 27, further comprising an antibiotic.

29. A bioresorbable implant comprising verapamil and mometasone.